发布求助
文献互助 智能选刊 最新文献

血液科学(英文)最新文献

筛选
英文 中文
Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis. 出血性直肠结肠炎患者与vedolizumab相关的获得性血友病。
血液科学(英文) Pub Date : 2023-01-01 DOI: 10.1097/BS9.0000000000000138
Thomas Schiestel
{"title":"Acquired hemophilia associated with vedolizumab in a patient with hemorrhagic rectocolitis.","authors":"Thomas Schiestel","doi":"10.1097/BS9.0000000000000138","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000138","url":null,"abstract":"To The Editor","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10717135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia. 基因多态性对中国急性淋巴细胞白血病患者甲氨蝶呤水平和毒性的影响。
血液科学(英文) Pub Date : 2023-01-01 DOI: 10.1097/BS9.0000000000000142
Qishan Hao, Yang Song, Qiuyun Fang, Yani Lin, Long Chen, Xiaodan Wang, Ping Zhang, Zhe Wang, Xiaoyuan Gong, Kaiqi Liu, Qinghua Li, Zheng Tian, Min Wang, Jianxiang Wang, Yingchang Mi
{"title":"Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia.","authors":"Qishan Hao,&nbsp;Yang Song,&nbsp;Qiuyun Fang,&nbsp;Yani Lin,&nbsp;Long Chen,&nbsp;Xiaodan Wang,&nbsp;Ping Zhang,&nbsp;Zhe Wang,&nbsp;Xiaoyuan Gong,&nbsp;Kaiqi Liu,&nbsp;Qinghua Li,&nbsp;Zheng Tian,&nbsp;Min Wang,&nbsp;Jianxiang Wang,&nbsp;Yingchang Mi","doi":"10.1097/BS9.0000000000000142","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000142","url":null,"abstract":"<p><p>Methotrexate (MTX) has an antitumor effect when used for the treatment of acute lymphoblastic leukemia (ALL). This study aims at evaluating the associations between 14 polymorphisms of six genes involved in MTX metabolism with serum MTX concentration and toxicity accompanying high-dose MTX. Polymorphisms in 183 Chinese patients with ALL were analyzed using TaqMan single nucleotide polymorphism genotyping assay. The serum MTX concentration was determined using homogeneous enzyme immunoassay. MTX-related toxicities were also evaluated. Renal toxicity was significantly associated with higher serum MTX concentrations at 24, 48, and 72 hours, and MTX elimination delay (<i>P</i> = 0.001, <i>P</i> < 0.001, <i>P</i> < 0.001, and <i>P</i> < 0.001, respectively), whereas <i>SLCO1B1</i> rs4149056 was associated with serum MTX concentrations at 48 and 72 hours, and MTX elimination delay in candidate polymorphisms (<i>P</i> = 0.014, <i>P</i> = 0.019, and <i>P</i> = 0.007, respectively). <i>SLC19A1</i> rs2838958 and rs3788200 were associated with serum MTX concentrations at 24 hours (<i>P</i> = 0.016, <i>P</i> = 0.043, respectively). <i>MTRR</i> rs1801394 was associated with serum MTX concentrations at 72 hours (<i>P</i> = 0.045). Neutropenia was related to <i>SLC19A1</i> rs4149056 (odds ratio [OR]: 3.172, 95% confidence interval [CI]: 1.310-7.681, <i>P</i> = 0.011). Hepatotoxicity was associated with <i>ABCC2</i> rs2273697 (OR: 3.494, 95% CI: 1.236-9.873, <i>P</i> = 0.018) and <i>MTRR</i> rs1801394 (OR: 0.231, 95% CI: 0.084-0.632, <i>P</i> = 0.004). Polymorphisms of <i>SLCO1B1, SLC19A1, ABCC2</i>, and <i>MTRR</i> genes help predict higher risk of increased MTX levels or MTX-related toxicities in adult ALL patients.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10661697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The eighth International Forum on Stem Cells: virtual meeting, October 20-21, 2022. 第八届干细胞国际论坛：虚拟会议，2022年10月20日至21日
血液科学(英文) Pub Date : 2022-12-27 eCollection Date: 2023-01-01 DOI: 10.1097/BS9.0000000000000147
Brian Eyden, Xiaochen Wang
{"title":"The eighth International Forum on Stem Cells: virtual meeting, October 20-21, 2022.","authors":"Brian Eyden, Xiaochen Wang","doi":"10.1097/BS9.0000000000000147","DOIUrl":"10.1097/BS9.0000000000000147","url":null,"abstract":",","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46010084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatially resolved transcriptomics: advances and applications. 空间解析转录组学:进展与应用。
血液科学(英文) Pub Date : 2022-11-04 eCollection Date: 2023-01-01 DOI: 10.1097/BS9.0000000000000141
Honglin Duan, Tao Cheng, Hui Cheng
{"title":"Spatially resolved transcriptomics: advances and applications.","authors":"Honglin Duan, Tao Cheng, Hui Cheng","doi":"10.1097/BS9.0000000000000141","DOIUrl":"10.1097/BS9.0000000000000141","url":null,"abstract":"<p><p>Spatial transcriptomics, which is capable of both measuring all gene activity in a tissue sample and mapping where this activity occurs, is vastly improving our understanding of biological processes and disease. The field has expanded rapidly in recent years, and the development of several new technologies has resulted in spatially resolved transcriptomics (SRT) becoming highly multiplexed, high-resolution, and high-throughput. Here, we summarize and compare the major methods of SRT, including imaging-based methods, sequencing-based methods, and in situ sequencing methods. We also highlight some typical applications of SRT in neuroscience, cancer biology, developmental biology, and hematology. Finally, we discuss future possibilities for improving spatially resolved transcriptomic methods and the expected applications of such methods, especially in the adult bone marrow, anticipating that new developments will unlock the full potential of spatially resolved multi-omics in both biological research and the clinic.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10717130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Immune checkpoint alterations and their blockade in COVID-19 patients. COVID-19患者免疫检查点改变及其阻断
血液科学(英文) Pub Date : 2022-10-01 Epub Date: 2022-08-01 DOI: 10.1097/BS9.0000000000000132
Jiaxiong Tan, Yangqiu Li
{"title":"Immune checkpoint alterations and their blockade in COVID-19 patients.","authors":"Jiaxiong Tan,&nbsp;Yangqiu Li","doi":"10.1097/BS9.0000000000000132","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000132","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) is a highly contagious disease that seriously affects people's lives. Immune dysfunction, which is characterized by abnormal expression of multiple immune checkpoint proteins (ICs) on immune cells, is associated with progression and poor prognosis for tumors and chronic infections. Immunotherapy targeting ICs has been well established in modulating immune function and improving clinical outcome for solid tumors and hematological malignancies. The role of ICs in different populations or COVID-19 stages and the impact of IC blockade remains unclear. In this review, we summarized current studies of alterations in ICs in COVID-19 to better understand immune changes and provide strategies for treating COVID-19 patients, particularly those with cancer.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592141/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40671465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Measurable residual disease in childhood B-cell acute lymphoblastic leukemia. 儿童b细胞急性淋巴细胞白血病可测量的残留病。
血液科学(英文) Pub Date : 2022-10-01 Epub Date: 2022-10-10 DOI: 10.1097/BS9.0000000000000112
Robert Peter Gale
{"title":"Measurable residual disease in childhood B-cell acute lymphoblastic leukemia.","authors":"Robert Peter Gale","doi":"10.1097/BS9.0000000000000112","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000112","url":null,"abstract":"In a recent report in Nature Cell Biology (2022. 24:242–52) Zhang and coworkers discuss comparative genetic and bio-chemical features of leukemia cells from children with B-cell acute lymphoblastic leukemia (ALL) obtained at diagnosis, in remission, and at relapse. 1 The authors analyzed large numbers of single-cell transcriptomes looking for dynamic changes and simultaneously, B-cell receptor sequences. They report that in contrast to leukemia cells at diagnosis, those at relapse shifted to a poorly-differentiated state. Changes in residual leukemia cells in remission were more complicated. Differential functional analyses highlighted activation of the hypoxia pathway in residual leukemia cells which correlated with drug resistance which was reversible with appropriate drug interventions in in vitro and in vivo models. The authors suggest this might be a therapy approach to eradicating measurable residual disease (MRD) in childhood B-cell ALL. This is a data dense article which requires understanding a machine learning algorithm. I suggest putting aside at least 5 hours to read and understand the text and supplement. I had to read it twice. This is not something to breeze through while texting on WeChat if you really want to understand the authors’ message and to critique it appropriately. First, a word on nomenclature. The authors use the term minimal residual disease . As John Goldman and I discussed several years ago the correct term is measurable residual disease . 2 Minimal is a subjective term; minimal to 1 person is not necessarily minimal to another. What we are considering is what can and cannot be measured in someone in complete histological remis- sion. (Another source of confusion; remissions are histological , not morphological . Morphology comes from the Greek μ&z. omicr; ρϕ which means form, structure or shape, not appear-ance). As an aside Morpheus was the Greek God of sleep and is the root of the drug name morphine. Lest you think I’m getting lost in semantics please recall the comment from George Orwell:","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40671464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex differences in normal and malignant hematopoiesis. 正常和恶性造血的性别差异。
血液科学(英文) Pub Date : 2022-10-01 Epub Date: 2022-08-16 DOI: 10.1097/BS9.0000000000000133
Xiaojing Cui, Xinghui Zhao, Ying Liang
{"title":"Sex differences in normal and malignant hematopoiesis.","authors":"Xiaojing Cui,&nbsp;Xinghui Zhao,&nbsp;Ying Liang","doi":"10.1097/BS9.0000000000000133","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000133","url":null,"abstract":"<p><p>Hematopoiesis is a continuous and well-regulated process requiring both the capacity for self-renewal and the potential for differentiation of hematopoietic stem cells. Multiple studies indicate that sex hormones exert significant effects on not only hematopoietic stem and progenitor cells, but also the development of hematopoietic lineages, resulting in sexual dimorphisms in normal hematopoiesis. Hematologic malignancies comprise a wide variety of cancers affecting the blood, bone marrow, and lymphatic system, such as leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative diseases. Overall, males are at greater risk and have worse prognosis for most of these malignancies compared with females. A better understanding of the differences between male and female could be of substantial value in research as well as clinical management.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/35/bs9-4-185.PMC9592170.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40671466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
BCR-ABL1 is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia. BCR-ABL1是JAK2V617F后原发性血小板增多症并发慢性髓性白血病患者的次要事件。
血液科学(英文) Pub Date : 2022-10-01 DOI: 10.1097/BS9.0000000000000129
Yanqing Zhang, Hailiang Bi, Ying Wang, Long Chen, Jiaqi Pan, Ping Xu, Wei Wang, Shaobin Yang
{"title":"<i>BCR-ABL1</i> is a secondary event after JAK2V617F in a patient with essential thrombocythemia who develop chronic myeloid leukemia.","authors":"Yanqing Zhang,&nbsp;Hailiang Bi,&nbsp;Ying Wang,&nbsp;Long Chen,&nbsp;Jiaqi Pan,&nbsp;Ping Xu,&nbsp;Wei Wang,&nbsp;Shaobin Yang","doi":"10.1097/BS9.0000000000000129","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000129","url":null,"abstract":"<p><p>Several cases such as myeloproliferative neoplasms (MPN) with the coexistence of JAK2 and BCR-ABL have been reported. However, cases of transformation of essential thrombocythemia (ET) into chronic myeloid leukemia (CML) during the disease progression were rarely reported. Here, we report the case of a patient with <i>JAK2 V617F</i>- positive ET who subsequently acquired BCR-ABL1, which transformed the disease into CML after 10 years from the initial diagnosis. In this study, we dynamically monitored JAK2 V617F and BCR-ABL and observed multiple gene mutations, including IDH2, IDH1, ASXL1, KRAS, and RUNX1. It is important to be aware of this potentially clone evolution in disease progression.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma. 复发性浆母细胞淋巴瘤患者达拉单抗治疗后的肺结核感染和巨细胞病毒再激活
血液科学(英文) Pub Date : 2022-10-01 DOI: 10.1097/BS9.0000000000000134
Wenyue Cao, Yuling Wan, Xingcheng Yang, Wei Huang, Jia Wei
{"title":"Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma.","authors":"Wenyue Cao,&nbsp;Yuling Wan,&nbsp;Xingcheng Yang,&nbsp;Wei Huang,&nbsp;Jia Wei","doi":"10.1097/BS9.0000000000000134","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000134","url":null,"abstract":"<p><p>Plasmablastic lymphoma (PBL) is an aggressive lymphoma with limited treatment strategies. Tuberculosis (TB) infection poses a high risk for patients with hematologic malignancies, especially those treated with immune agents but were never reported post-daratumumab treatment. Herein, we reported a TB infection in a 57-year-old male diagnosed with HIV-negative PBL receiving daratumumab-based treatment, who showed atypical lung infection and yielded <i>Mycobacterium tuberculosis</i> and cytomegalovirus (CMV) in the bronchoalveolar lavage fluid. Anti-TB therapy was administered, and the following daratumumab treatment was complete with good tolerance. In this case, we demonstrated that TB infection might occur after daratumumab therapy, and adequate attention should be paid to atypical symptoms.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10362509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel non-viral PDCD1 site-integrated CAR design: killing 2 birds with 1 stone. 一种新的非病毒PDCD1位点集成CAR设计:一石二鸟。
血液科学(英文) Pub Date : 2022-10-01 DOI: 10.1097/BS9.0000000000000135
Yuanbin Cui, Yunlin Huang, Le Qin, Peng Li
{"title":"A novel non-viral <i>PDCD1</i> site-integrated CAR design: killing 2 birds with 1 stone.","authors":"Yuanbin Cui,&nbsp;Yunlin Huang,&nbsp;Le Qin,&nbsp;Peng Li","doi":"10.1097/BS9.0000000000000135","DOIUrl":"https://doi.org/10.1097/BS9.0000000000000135","url":null,"abstract":"Although chimeric antigen receptor T-cell (CAR-T-cell) ther- apy has shown excellent efficacy against refractory/relapsed B-cell lymphoma","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10362503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信